RxDoctor Payments Data

Marcy Southwell, PA

Medical · Concord, NHNPI 1306882881

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 32.8% of the total. Reporting peaked in 2022 at $387 and has fallen 98.4% since, to $6 in 2025.

$887in general payments, 2019–2025

Across 46 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$291
  • Bristol Myers Squibb$137
  • Takeda Pharmaceuticals U.S.A., Inc.$82
  • Ferring Pharmaceuticals Inc.$80
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$64
  • Janssen Scientific Affairs, LLC$63
  • plus $171 from 6 others

What the payments were for

  • Food & beverage$887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$887 in reported general payments places this provider in the 80th percentile of 124 medical providers in New Hampshire.

See all medical providers in New Hampshire

Medicare billing

Part B allowed, 2024
$29,967
Medicare patients
262
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$441,193
XifaxanRifaximin38$126,625
Mesalamine50$28,566
LinzessLinaclotide47$25,085
Alosetron Hcl13$5,149
Ursodiol22$3,658
Colestipol Hcl11$1,900
Lactulose32$1,804
Pantoprazole Sodium122$1,545
Nadolol19$1,192
Mesalamine ErMesalamine13$741
Omeprazole83$731
Azathioprine22$581
Lansoprazole12$470
Dicyclomine Hcl36$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$57$441,19315 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$64$126,62538 claims
AbbVieLinzess$291$25,08547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 124 medical providers in New Hampshire.

Other medical in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →